Redox-Responsive Dipeptide Nanostructures toward Targeted Cancer Therapy.

Area of Science:

• Biomaterials Science
• Nanotechnology
• Drug Delivery Systems

Background:

• Responsive materials are crucial for targeted drug delivery.
• Developing stimuli-responsive nanoparticles for cancer therapy is an active research area.

Purpose of the Study:

• To engineer cancer-targeted, redox-responsive nanoparticles (NPs) using disulfide-linked oxidized cysteine-phenylalanine (CFO).
• To load anticancer drug doxorubicin (Dox) into these NPs for controlled release.
• To evaluate the targeted delivery, cellular uptake, and therapeutic efficacy of the developed NPs.

Main Methods:

• Synthesis of disulfide-linked oxidized cysteine-phenylalanine (CFO) nanoparticles.
• Conjugation of folic acid (FA) to CFO nanoparticles for cancer cell targeting.
• Loading of doxorubicin (Dox) into FA-conjugated CFO nanoparticles (FA-CFO-Dox-NPs).
• In vitro evaluation of nanoparticle uptake in cancer cells (C6 glioma, B16F10 melanoma) and normal cells (HEK293T).
• Assessment of stimuli-responsive drug release in the presence of glutathione (GSH).
• Cytotoxicity studies of FA-CFO-Dox-NPs in cancer cell lines.

Main Results:

• Successfully developed disulfide-linked nanoparticles (CFO-Dox-NPs) capable of stimuli-responsive drug release in the presence of glutathione (GSH).
• FA-conjugated NPs (FA-CFO-NPs) exhibited enhanced uptake in cancer cells compared to normal cells due to folate receptor overexpression.
• Doxorubicin-loaded FA-CFO-NPs demonstrated superior cytotoxicity against C6 and B16F10 cancer cells compared to free doxorubicin.

Conclusions:

• The developed disulfide-linked nanoparticle system shows promise as a selective drug delivery platform for cancer therapy.
• FA-targeting and GSH-responsiveness enable efficient drug accumulation and release within cancer cells.
• This approach offers a potential strategy for improving the efficacy and reducing side effects of anticancer drugs.